Regenerative effects of RKI-1447 on human corneal endothelial cells: a comparative study.

Area of Science:

• Ophthalmology
• Cell Biology
• Pharmacology

Background:

• Rho-associated protein kinase (ROCK) inhibitors are investigated for their effects on ocular tissues.
• Human corneal endothelial cells (HCECs) play a crucial role in maintaining corneal clarity.
• Understanding factors that promote HCEC proliferation and wound healing is vital for treating corneal diseases.

Purpose of the Study:

• To compare the efficacy of two ROCK inhibitors, Y-27632 and RKI-1447, in promoting HCEC proliferation and wound healing.
• To evaluate the impact of these inhibitors on ROCK activity in HCECs.

Main Methods:

• Primary HCECs were divided into control, Y-27,632-treated, and RKI-1447-treated groups.
• Cell proliferation was assessed using 5-bromo-2-deoxyuridine (BrdU) incorporation.
• Wound healing capacity was analyzed using ImageJ software.
• ROCK activity was measured via enzyme-linked immunosorbent assay (ELISA).

Main Results:

• Both RKI-1447 (1 µM) and Y-27,632 (10 µM) significantly increased HCEC proliferation compared to controls (p < 0.05).
• RKI-1447 demonstrated a more potent proliferative effect than Y-27,632 (p < 0.05).
• Endothelial wound healing was accelerated by RKI-1447 compared to control and Y-27,632 groups (p < 0.05), while Y-27,632 showed a transient effect within 24 hours.

Conclusions:

• RKI-1447 exhibited superior potency over Y-27,632 in enhancing HCEC proliferation, accelerating endothelial wound healing, and suppressing ROCK activity.
• This pilot study suggests RKI-1447 as a promising therapeutic agent for corneal endothelial disorders.
• Further in vitro and in vivo preclinical investigations are necessary to establish the efficacy and ocular safety of RKI-1447 prior to clinical application.